spacer
home > pmps > winter 2019 > the heart of healthcare
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Heart of Healthcare

Over the last decade, many pharmaceutical companies have moved from mass market drug development to investing in niche speciality medicines. This shift in the pharma industry has been driven by the recognition that the sector’s traditional blockbuster model had become unsustainable.

This is good news for patients with rare diseases. The rise of speciality treatments for chronic, complex, and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients.

According to IQVIA (formerly Quintiles and IMS Health), speciality medicines have enjoyed a decade of continued growth, which has put them on course to overtake the value of spending on traditional drugs in many of the world’s biggest pharma markets by 2022.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Chapper is the CEO at CHAPPER healthcare. He joined CHAPPER healthcare in 2013 from a successful career in law, where he worked at leading city law firms, as well as in an investment bank. Jonathan brought with him a wealth of commercial and legal experience, which he now applies to the pharma industry. CHAPPER healthcare is a leading specialist wholesaler and distributor and supplies pharmaceuticals to over 60 countries worldwide.
spacer
Jonathan Chapper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement